Results 201 to 210 of about 548,008 (322)

Neoadjuvant therapy in skin cancer: current evidence and future perspectives

open access: yesJDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary The development of immune checkpoint inhibitors and targeted therapies has fundamentally changed the treatment of cutaneous malignancies, especially in squamous cell carcinoma, melanoma, and Merkel cell carcinoma. The latest neoadjuvant approaches have shown promising results in locally advanced stages.
Lea Daniello   +2 more
wiley   +1 more source

Fragment-based drug design of a bacterial kinase inhibitor capable of increasing the antibiotic sensitivity of clinical isolates. [PDF]

open access: yesCommun Chem
Kowalewski J   +10 more
europepmc   +1 more source

A multi‐level process perspective on refugee workplace integration

open access: yesEuropean Management Review, EarlyView.
Abstract Prior research has suggested the need for complementary efforts by multiple stakeholders (government, NGOs, employers) to support workplace integration for refugees, but has paid less attention to how such programs are developed and enacted in specific settings, and how they then influence refugees' workplace integration trajectories.
Vedran Omanović, Ann Langley
wiley   +1 more source

Leishmania donovani's protein tyrosine phosphatases interact with DUF21 and respond to environmental magnesium

open access: yesThe FEBS Journal, EarlyView.
The Leishmania phosphatase PTP1, and possibly the genetically similar PTP2, interacts with the Leishmania transmembrane protein DUF21. When both ptp1 and ptp2 are knocked out of Leishmania (LdΔPTP1/2), the parasite can no longer survive without magnesium in vitro and has reduced viability in the host macrophage. Conversely, in duf21 knockout (LdΔDUF21),
Kayla Paulini   +6 more
wiley   +1 more source

Super‐Response to Guselkumab Treatment in Patients With Moderate‐to‐Severe Psoriasis: Real‐World Data With Up to Five Years of Follow‐Up in The Czech Republic

open access: yesInternational Journal of Dermatology, EarlyView.
Super‐response to Guselkumab. ABSTRACT Background Guselkumab, a selective interleukin (IL)‐23 inhibitor, is approved for the treatment of moderate‐to‐severe plaque psoriasis. While randomized clinical trials have introduced the concept of “super‐responders” (SRe)—patients achieving complete skin clearance (Psoriasis Area and Severity Index [PASI] 100 ...
Martina Kojanova   +76 more
wiley   +1 more source

Home - About - Disclaimer - Privacy